



AMENDMENTS TO THE CLAIMS

Please cancel claims 1-26 and 40-45 as follows:

1-26. (Canceled)

27. (Original) A method of increasing an immune response in a subject comprising administering to the subject a cell transformed to express on its surface a component which binds to an Fc receptor of an effector cell.

28. (Original) The method of claim 27 further comprising administering to the subject an agent that increases expression of Fc receptors on effector cells.

29. (Original) The method of claim 28, wherein the agent is a cytokine.

30. (Original) The method of claim 29, wherein the cytokine is selected from the group consisting of G-CSF, GM-CSF, IFN- γ , TNF, and combinations thereof.

31. (Original) The method of claim 27, wherein the cell is a tumor cell.

32. (Original) The method of claim 27, wherein the cell is transformed *ex vivo*, and then administered to the subject.

33. (Original) A method of increasing an immune response to an antigen, comprising transforming a cell which expresses the antigen with a nucleic acid encoding a protein which binds to an Fc receptor on an effector cell; and contacting the cell with an effector cell in the presence of a lymphocyte.

34. (Original) The method of claim 33 wherein transforming the cell is performed *ex vivo*, and contacting the cell with an effector cell is performed *in vivo*.

35. (Original) The method of claim 35, wherein the nucleic acid encodes an antibody or antigen binding fragment thereof.

36. (Original) The method of claim 33, wherein the antibody comprises antibody H22 having ATCC number CRL 11,177, or antibody A77.

37. (Original) The method of claim 36, wherein the antibody fragment comprises a single chain Fv fragment of H22 or A77.

38. (Original) The method of claim 33, wherein the nucleic acid encodes a fusion protein comprising an antibody or antibody fragment and a transmembrane protein.

39. (Original) The method of claim 33, wherein the antigen is selected from the group consisting of a tumor antigen and a component of a pathogen.

40-45. (Canceled)